Company Filing History:
1 out of 1 
1 out of 70 
Years Active: 2017
Title: Miwako Narita: Innovator in Leukemia Therapeutics
Introduction
Miwako Narita is a prominent inventor based in Niigata, Japan. She has made significant contributions to the field of leukemia research through her innovative work in nucleic acid technology. Her dedication to advancing therapeutic options for leukemia patients is evident in her patented inventions.
Latest Patents
Miwako Narita holds a patent for a heptamer-type small guide nucleic acid that induces apoptosis of human leukemia cells. This invention comprises various 7-base sequences and serves as a potential therapeutic agent for leukemia. The novel heptamer-type small guide nucleic acid can effectively induce apoptosis in human leukemia cells, offering hope for improved treatment options.
Career Highlights
Throughout her career, Miwako Narita has been associated with esteemed institutions such as Niigata University of Pharmacy and Applied Life Science and Niigata University. Her work in these academic settings has allowed her to focus on research that bridges the gap between science and practical therapeutic applications.
Collaborations
Miwako Narita has collaborated with notable colleagues, including Masayuki Nashimoto and Masuhiro Takahashi. These partnerships have contributed to her research and the development of her innovative therapeutic solutions.
Conclusion
Miwako Narita's contributions to leukemia research through her patented inventions highlight her role as a leading innovator in the field. Her work continues to inspire advancements in therapeutic strategies for leukemia treatment.